XSHG600380
Market cap2.93bUSD
Dec 25, Last price
11.42CNY
1D
0.26%
1Q
8.97%
Jan 2017
27.03%
Name
Joincare Pharmaceutical Group Industry Co Ltd
Chart & Performance
Profile
Joincare Pharmaceutical Group Industry Co., Ltd. engages in the research, development, production, and sale of pharmaceuticals and healthcare products primarily in China. The company offers chemical drug preparation products, including respiration, gastroenterology, anti-infection, gonadotropic, and psychiatric products; and traditional chinese drug preparation production, which includes anti-tumor and cold products. It also provides chemical APIs and intermediates; diagnostic reagents and equipment, including autoimmunity multiple detection platform and diagnostic kit for IgM; and healthcare products, which includes American ginseng tea and Jingxin menocare essence. In addition, the company engages in the wholesale and retail of skin care products, cosmetics, and other necessities. It offers its products in various forms, such as hormone tablets, oral liquids, and tablets. The company was founded in 1992 and is headquartered in Shenzhen, China.
Valuation
Title CNY in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
---|---|---|---|---|---|---|---|---|---|---|
2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | 2015‑12 | 2014‑12 | |
Income | ||||||||||
Revenues | 16,646,350 -2.90% | 17,142,753 7.79% | 15,903,688 17.62% | |||||||
Cost of revenue | 12,172,065 | 13,165,449 | 12,433,899 | |||||||
Unusual Expense (Income) | ||||||||||
NOPBT | 4,474,285 | 3,977,304 | 3,469,789 | |||||||
NOPBT Margin | 26.88% | 23.20% | 21.82% | |||||||
Operating Taxes | 614,536 | 562,009 | 339,480 | |||||||
Tax Rate | 13.73% | 14.13% | 9.78% | |||||||
NOPAT | 3,859,749 | 3,415,295 | 3,130,309 | |||||||
Net income | 1,442,780 -50.15% | 2,894,096 10.76% | 2,612,849 1.33% | |||||||
Dividends | (336,792) | (277,558) | (288,675) | |||||||
Dividend yield | 1.42% | 1.30% | 1.16% | |||||||
Proceeds from repurchase of equity | (821,537) | (1) | ||||||||
BB yield | 3.47% | 0.00% | ||||||||
Debt | ||||||||||
Debt current | 2,076,159 | 2,189,128 | 2,610,061 | |||||||
Long-term debt | 3,153,119 | 3,277,809 | 876,924 | |||||||
Deferred revenue | 384,537 | 433,543 | ||||||||
Other long-term liabilities | 460,180 | 84,000 | 78,000 | |||||||
Net debt | (14,157,591) | (11,955,393) | (11,070,477) | |||||||
Cash flow | ||||||||||
Cash from operating activities | 3,928,910 | 3,977,705 | 2,563,089 | |||||||
CAPEX | (1,130,149) | |||||||||
Cash from investing activities | (1,021,591) | |||||||||
Cash from financing activities | (1,936,644) | 566,123 | ||||||||
FCF | 4,006,982 | 2,940,766 | 2,243,649 | |||||||
Balance | ||||||||||
Cash | 16,181,164 | 14,917,504 | 11,913,869 | |||||||
Long term investments | 3,205,706 | 2,504,826 | 2,643,593 | |||||||
Excess cash | 18,554,552 | 16,565,192 | 13,762,278 | |||||||
Stockholders' equity | 20,428,080 | 20,145,722 | 18,026,751 | |||||||
Invested Capital | 9,759,013 | 11,029,325 | 10,120,171 | |||||||
ROIC | 37.13% | 32.30% | 34.26% | |||||||
ROCE | 15.66% | 14.29% | 14.40% | |||||||
EV | ||||||||||
Common stock shares outstanding | 1,907,177 | 1,896,977 | 1,937,153 | |||||||
Price | 12.43 10.10% | 11.29 -12.07% | 12.84 -7.69% | |||||||
Market cap | 23,706,215 10.69% | 21,416,875 -13.90% | 24,873,043 -8.59% | |||||||
EV | 18,432,253 | 18,359,890 | 22,161,883 | |||||||
EBITDA | 5,528,379 | 4,815,006 | 4,090,243 | |||||||
EV/EBITDA | 3.33 | 3.81 | 5.42 | |||||||
Interest | 146,728 | 139,016 | 90,278 | |||||||
Interest/NOPBT | 3.28% | 3.50% | 2.60% |